ImmunoGen, Inc. (IMU.F)

4.5470 -0.0530 (-1.15%) At close: 08:02AM CET

ImmunoGen, Inc.

830 Winter Street
Waltham, MA 02451-1477
United States
781 895 0600
https://www.immunogen.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 79

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Mark Joseph Enyedy	Pres, CEO & Director	1.21M	N/A	1964
Ms. Susan Altschuller Ph.D.	Sr. VP & CFO	391.21k	N/A	1982
Dr. Theresa G. Wingrove	Sr. VP of Regulatory Affairs & Quality	548.21k	N/A	1958
Dr. Anna Berkenblit	Sr. VP & Chief Medical Officer	641.74k	N/A	1970
Ms. Stacy A. Coen	Sr. VP & Chief Bus. Officer	388.97k	N/A	1971
Ms. Renee Lentini	VP of Fin., Principal Accounting Officer & Corp. Controller	N/A	N/A	1978
Dr. Thomas Ryll	Sr. VP of Technical Operations	N/A	N/A	1961
Ms. Courtney O'Konek	Sr. Director of Corp. Communications & Investor Relations	N/A	N/A	N/A
Ms. Audrey Bergan	VP & Chief HR Officer	N/A	N/A	N/A
Ms. Kristen Harrington-Smith	Sr. VP & Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Corporate Governance

ImmunoGen, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 5. The pillar scores are Audit: 6; Board: 5; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.